QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change in SGRQ total score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg leads to lower rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (high certainty).
1 finding from 1 review
Moderate‐to‐severe exacerbations (rate) · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations All participants compared with placebo (moderate certainty).
1 finding from 1 review
Time to first moderate or severe exacerbation Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (high certainty).
1 finding from 1 review
Time to first moderate or severe exacerbation All participants · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in time to first moderate or severe exacerbation All participants compared with placebo (moderate certainty).
1 finding from 1 review
Rate of exacerbations with ED visit or hospitalisations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations Eosinophilic… compared with placebo (moderate certainty).
1 finding from 1 review
Rate of exacerbations requiring emergency department treatment or admission · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations All… compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Generic quality of life measures · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma
1 finding from 1 review